Sysmex (OTCMKTS:SSMXY) Stock Price Down 7% – What’s Next?

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s share price traded down 7% during mid-day trading on Wednesday . The company traded as low as $11.70 and last traded at $11.70. Approximately 1,555 shares traded hands during trading, a decline of 99% from the average daily volume of 210,893 shares. The stock had previously closed at $12.5750.

Analyst Ratings Changes

Separately, Zacks Research downgraded shares of Sysmex from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold”.

Sysmex Stock Performance

The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 2.46. The stock has a 50-day moving average price of $9.52 and a 200-day moving average price of $9.11. The company has a market capitalization of $7.69 billion, a price-to-earnings ratio of 29.07 and a beta of 1.05.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings results on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. Sysmex had a return on equity of 7.87% and a net margin of 7.62%.The business had revenue of $825.85 million for the quarter, compared to analysts’ expectations of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. As a group, analysts forecast that Sysmex Corporation ADR will post 0.38 earnings per share for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.